

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
25 August 2005 (25.08.2005)

PCT

(10) International Publication Number
WO 2005/078075 A2

(51) International Patent Classification⁷: **C12N 9/00**

MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:
PCT/EP2005/050174

(22) International Filing Date: 17 January 2005 (17.01.2005)

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
04075430.1 11 February 2004 (11.02.2004) EP

Declaration under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)



(71) Applicant (for all designated States except US): UNIVERSITE DE LIEGE [BE/BE]; Interface Entreprises-Université, Antheunis, Nicole, Quai Van Beneden, 25, B-4020 Liège (BE).

(72) Inventors; and
(75) Inventors/Applicants (for US only): GIANNOTTA, Fabrizio [BE/BE]; Rue E.Malvoz 10 bte 3, B-4300 Waregem (BE). FILEE, Patrice [BE/BE]; Rue Lassaux, 33, B-4020 Jupille (BE). GALLENI, Moreno [BE/BE]; Rue des Tombes, 14, B-4557 Fraiture (BE). FRERE, Jean-Marie [BE/BE]; Chemin de Sotrez, 85, B-4550 Nandrin (BE). JORIS, Bernard [BE/BE]; Chemin des Moutons, 66, B-4900 Spa (BE). BRANS, Alain [BE/BE]; Au Tiège, 21, B-4052 Beaufays (BE). RUTH, Nadia [BE/BE]; Rue de Stavelot, 17, B-4020 Liege (BE).

(74) Common Representative: UNIVERSITE DE LIEGE; Interface Entreprises-Université, Antheunis, Nicole, Quai Van Beneden, 25, B-4020 Liège (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,

Published:

- without international search report and to be republished upon receipt of that report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/078075 A2

(54) Title: HYBRID PROTEINS OF ACTIVE-SITE SERINE BETA-LACTAMASE.

(57) Abstract: The present invention refers to a recombinant nucleotide sequence which codes upon expression for at least a part of a bifunctional hybrid active-site serine β -lactamase protein, wherein the β -lactamase protein is bearing at least one heterologous sequence, wherein in that the hybrid protein is having two functions, the first function is associated with the β -lactamase portion and the second function is associated with the heterologous sequence having a biological function which is different from the first function.